3Cs Community - Capital, Commitment, Connections - click to go Home
WELCOME TO 3CS COMMUNITY
 
Privacy Policy


3Cs Forum

Join our group on
Linkedin


Next Meetings

full details here


Our Partners

UCL Advances
taylor wessing 150x70
reed smith logo 23039
pinsentmasons-logo
angelsdennew150x70

May 2005

London - 24 May 2005 - KSB LawOur May meeting was hosted by KSB Law .

Guest Speakers:Paul Bowman, Director New Business Development, Bank of ScotlandBank lending to small businesses and the use of the Small Firm Loan Guarantee Scheme - a Banker's PerspectiveRon Gould, Managing Director and founder of Qdos Consulting.Qdos are specialists in taxation, VAT, employment law, health & safety and legal fees insurance, with a UK-wide network of associates and clients. Qdos are also the UK's leading authority on IR35 having taken over 600 cases, and conceding only one. Qdos is listed at 19 in Sunday Times Fast Track 100 annual league table for 2004.

Business Pitches:Stuart Harvey - Wot no Power?For individuals, householders and companies and local government who want to feel secure that they have electrical power. Wot no Power power systems are a low cost, high availability backup power turn-key product. In contrast to highly priced, fully featured diesel sets, our product has been designed for low cost of ownership, for both initial purchase & running costs.John Culbert, Managing Director of AssenticThe recent Housing Bill will change the way residential property is sold and favours the larger corporations. However, the majority (75%) of vendors prefer to deal with local owner managed firms of estate agents, conveyancers and surveyors. Assentics rich client collaboration platform will champion the small to medium firms and link all the parties involved in each transaction. This enables the professionals from disparate organisations, to form into temporary teams each focused on the sale of a property.Mark Tucker, CEO of g-Nosticsg-Nostics Ltd was founded to commercialise innovative technology in the pharmacogenetic sector. Using a simple finger-prick test we identify each persons unique molecular profile and then use the information to predict individual response to drug therapy. This pharmacogenetic technology can identify the best treatment with lowest risk of side effects in a wide range of medical conditions. The NicoTest for smoking cessation as a lead product, is ground-breaking because it offers significantly improved cessation rates through a more convenient and lower cost method.